- Delivering Pan India
Rcnet® (Sunitinib Malate) Sunitinib malate 12.5 mg capsules by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Sunitinib malate 12.5 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | Sunitinib malate 12.5 mg: 1 x 7 capsules |
| Storage | As per carton and leaflet; original pack |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Rcnet® (Sunitinib Malate) Sunitinib malate 12.5 mg Capsules — Oral Multi-Targeted Kinase Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Rcnet® is a brand of sunitinib malate capsules, an oral kinase inhibitor, marketed by BDR Pharmaceuticals. According to the US prescribing information for the reference product (Sutent®), sunitinib is indicated for gastrointestinal stromal tumor (GIST) after progression on or intolerance to imatinib, advanced renal cell carcinoma (RCC), adjuvant treatment of RCC at high risk of recurrence after nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors. Indications for Rcnet in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe sunitinib malate, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Rcnet® (sunitinib malate) Sunitinib malate 12.5 mg capsules to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Rcnet contains sunitinib malate, an oral kinase inhibitor. The Rcnet carton shown on this page states sunitinib malate capsules 12.5 mg, 1 x 7 capsules.
How it works, according to the label: The reference label describes sunitinib as a kinase inhibitor. It carries a boxed warning for hepatotoxicity.
The current US prescribing information for SUTENT® (sunitinib malate capsules) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Rcnet pack insert.
The Sutent label summarises its Clinical Studies by indication. In metastatic renal cell carcinoma, a randomised trial compared sunitinib with interferon alfa; it was published by Motzer et al. in the New England Journal of Medicine in 2007. Full results are in the DailyMed prescribing information. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Sunitinib malate 12.5 mg | Capsules (oral) | 1 x 7 capsules |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and urology department buyers, and pharmacies that source oral oncology products. Sunitinib is prescribed and supervised by a physician, as described in the prescribing information.
The Sutent label lists, as most common adverse reactions (25% or more), fatigue or asthenia, diarrhea, mucositis or stomatitis, nausea, decreased appetite, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, altered taste, dyspepsia and thrombocytopenia. It carries a boxed warning for severe and sometimes fatal hepatotoxicity, and warns of cardiovascular events, QT prolongation and hypertension. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Rcnet carton and leaflet. For reference, the US Sutent label describes storage at controlled room temperature, 20°C to 25°C. Keep in the original pack, out of reach of children.
Rcnet is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Rcnet through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Rcnet available in India?
A.K. Pharma supplies Rcnet (sunitinib malate) Sunitinib malate 12.5 mg capsules to hospitals and pharmacies in India. Contact us for current availability.
What does Rcnet contain?
Sunitinib malate 12.5 mg per capsule, an oral kinase inhibitor, in a pack of 7 capsules.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Rcnet be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
